#Canada #Halifax #JP Morgan #ABK Biomedical #Eye90

ABK Biomedical Secures Major Funding

On October 14, 2025, ABK Biomedical, Inc., a Halifax-based company known for its cutting-edge medical devices, announced it has raised US$35 million in an oversubscribed Series D financing round. This financing, led by J.P. Morgan Life Sciences Private Capital, aims to accelerate the development and commercialization of their pioneering Eye90 microspheres®.

A Boost for Innovation

The Series D funding includes participation from prominent investors such as F-Prime, Santé Ventures, and Eight Roads Ventures. The funds are designed to bolster ABK's ongoing clinical operations and prepare the company for the commercialization phase of its Eye90 microspheres, which has been recognized by the FDA under the Breakthrough Device Designation. This designation spotlights Eye90’s potential to treat serious medical conditions more effectively, especially hepatocellular carcinoma (HCC), a severe form of liver cancer.

Joe Siletto, a Managing Partner at J.P. Morgan, expressed his enthusiasm about ABK Biomedical's progress since its previous financing round, stating, "ABK has demonstrated impressive advancements that position them well within the medical device landscape."

The Future of Eye90 Microspheres

The Eye90 microspheres are designed to improve the treatment of liver cancer through a method known as Yttrium-90 (Y90) radioembolization. This innovative technology aims to deliver targeted radiation to tumors, providing a new avenue for patients with limited treatment options. Alongside the funding, ABK Biomedical is focused on scaling its manufacturing and supply chain operations to ensure sustainable market presence.

Mike Mangano, President and CEO of ABK Biomedical, shared his thoughts on the funding round, stating, "We are incredibly grateful for the investor interest we have received. This funding will enable our exceptional team to continue meeting our product development objectives and executing our FDA IDE pivotal trial for Eye90 microspheres."

ABK’s ongoing Route90 trial aims to provide robust data that can validate the effectiveness of the microspheres, and the results are anticipated to be a crucial part of the company’s future. Mangano noted the exceptional diligence of everyone involved in the trial, emphasizing its potential for yielding one of the most comprehensive data sets in the field of Interventional Oncology.

Investor Confidence and Market Growth

The success of this funding round also reflects the robust collaboration between ABK Biomedical and its investors. Ketan Patel, M.D. of F-Prime, remarked, "The advanced design of the Eye90 microspheres along with its innovative delivery system positions us for significant market advancement in a rapidly growing sector of interventional oncology."

With the backing of influential investors and the pursuit of regulatory approvals, ABK Biomedical is set on a promising trajectory in the medical device domain. As it continues to innovate, the company aims to improve outcomes and lives of patients suffering from both benign and malignant hypervascular tumors.

About ABK Biomedical

Established to enhance treatment outcomes, ABK Biomedical is focused on the research, development, and commercialization of medical device therapies. The company has developed a unique portfolio of embolic products, with a strong emphasis on advanced technology and innovative therapeutic approaches. These efforts are supported by its intellectual capital and the technical expertise housed within its dedicated research and manufacturing facilities.

In conclusion, ABK Biomedical's current financing underscores a pivotal moment not only for their advancement but also for the broader landscape of medical technology, promising to redefine patient care in oncology.

Next Steps

As ABK Biomedical moves forward, the incorporation of this funding will be vital in not just achieving their operational goals but in their efforts to make strides towards regulatory approval for their innovative products, cementing their place in the future of medical device solutions.